Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab versus nivolumab + ipilimumab versus chemotherapy in MSI-H/dMMR metastatic colorectal cancer
NL-OMON60293Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nivolumab and ipilimumab in colorectal cancer (CRC), metastatic colon cancer (mCRC) and microsatellite unstable colorectal cancer (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Progression-Free Survival by Blinded Independent Central Review. Started Oct 2019; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
colorectal cancer (CRC)metastatic colon cancer (mCRC)microsatellite unstable colorectal cancer
Beyond the preview
Go deeper on NL-OMON60293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60293.